Over the past few decades, efforts to slow the increase in cases of pediatric atopic dermatitis (AD), combined with a focus on the health benefits of breast-feeding, have led to the question of whether breast-feeding can reduce the risk of AD.
Therapeutics is one of the most significant challenges in pediatric dermatology. Children have been identified as “therapeutic orphans”, with few options that have FDA-approved pediatric indications. Access to new and novel treatments like biologics is especially limited. Supportive legislation, beginning with the Best Pharmaceuticals for Children Act (bpca.nichd.nih.gov), has marked the dawn of a new era.
Positive results of an open-label, multicenter trial support the use of a gel body wash containing 0.006 percent sodium hypochlorite (CLn Body Wash, Top MD Skin Care) as an adjunct in the management of atopic dermatitis (AD), according to researchers who presented their findings at the 2014 annual meeting of the American Academy of Dermatology.